Highlighted transactions



Celyad SA

Piper Sandler served as joint bookrunner on the $100.1 million IPO for Celyad SA.

Client Description

Celyad SA is a leader in engineered cell therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology. The company's lead drug product candidate in cardiovascular disease is C-Cure, an autologous cell therapy for the treatment of patients with ischemic heart failure, or HF.